Patents by Inventor Roger P. Dickinson
Roger P. Dickinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5618941Abstract: Compounds of formula (I) wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each H or C.sub.1 -C.sub.4 alkyl; R.sup.5 is (CH.sub.2).sub.m NHSO.sub.2 R.sup.6 or (CH).sub.m NHCOR.sup.6 ; R.sup.6 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl optionally substituted by aryl, aryl or heteroaryl; R.sup.7 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, OCF.sub.3, CN, CONH.sub.2, or S(O).sub.n (C.sub.1 -C.sub.4 alkyl); X is CH.sub.2, CHCH.sub.3, CH(OH), C(OH)CH.sub.3, C.dbd.CH.sub.2, CO or O; m is 0 or 1 and n is 0, 1 or 2, and their pharmaceutically acceptable salts and biolabile esters, are antagonists of thromboxane A.sub.2 of utility, particulary in combination with a thromboxane synthetase inhibitor, in the treatment of atherosclerosis and unstable angina and for prevention of reocclusion after percutaneous transluminal angioplasty.Type: GrantFiled: March 15, 1995Date of Patent: April 8, 1997Assignee: Pfizer Inc.Inventors: Roger P. Dickinson, Kevin N. Dack, John Steele
-
Patent number: 5502065Abstract: The present invention provides compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 21, 1994Date of Patent: March 26, 1996Assignee: Pfizer Inc.Inventors: Alan D. Brown, Roger P. Dickinson, Martin J. Wythes
-
Patent number: 5457118Type: GrantFiled: April 20, 1994Date of Patent: October 10, 1995Assignee: Pfizer Inc.Inventors: Roger P. Dickinson, Kevin N. Dack, John Steele
-
Patent number: 5364938Abstract: The invention provides antifungal agents of the formula: ##STR1## and their pharmaceutically acceptable salts, whereinR is phenyl optionally substituted by 1 to 3substituents each independently selected from halo and CF.sub.3 ;R.sup.1 is C.sub.1 -C.sub.4 alkyl;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl; and"Het", which is attached to the adjacent carbon atom by a ring carbon atom, is selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, "Het" being optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, CN, NO.sub.2, NH.sub.2, --NH(C.sub.1 -C.sub.4 alkanoyl) or --NHCO.sub.2 (C.sub.1 -C.sub.4 alkyl).Type: GrantFiled: March 4, 1993Date of Patent: November 15, 1994Assignee: Pfizer Inc.Inventors: Roger P. Dickinson, Kenneth Richardson
-
Patent number: 5206364Abstract: The invention provides antifungal agents of the formula: ##STR1## and their pharmaceutically acceptable salts, wherein R is phenyl optionally substituted by 1 to 3 substituents each independently selected from halo and CF.sub.3 ;R.sup.1 is C.sub.1 -C.sub.4 alkyl;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl; and"Het", which is attached to the adjacent carbon atom by a ring carbon atom, is selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, "Het" being optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, CN, NO.sub.2, NH.sub.2, --NH(C.sub.1 -C.sub.4 alkanoyl) or --NHCO.sub.2 (C.sub.1 -C.sub.4 alkyl).Type: GrantFiled: March 4, 1992Date of Patent: April 27, 1993Assignee: Pfizer Inc.Inventors: Roger P. Dickinson, Kenneth Richardson
-
Patent number: 5116844Abstract: The invention provides antifungal agents of the formula: ##STR1## and their pharmaceutically acceptable salts, wherein R is phenyl optionally substituted by 1 to 3 substituents each independently selected from halo and CF.sub.3 ;R.sup.1 is C.sub.1 -C.sub.4 alkyl;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl; and"Het", which is attached to the adjacent carbon atom by a ring carbon atom, is selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, "Het" being optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, CN, NO.sub.2, NH.sub.2, --NH(C.sub.1 -C.sub.4 alkanoyl) or --NHCO.sub.2 (C.sub.1 -C.sub.4 alkyl).Type: GrantFiled: August 11, 1989Date of Patent: May 26, 1992Assignee: Pfizer Inc.Inventors: Roger P. Dickinson, Kenneth Richardson
-
Patent number: 5057528Abstract: A series of novel aryloxyalkylamino - and arylaminoalkylamino-pyridine and imidazole compounds have been prepared, including their pharmaceutically acceptable salt, wherein the aryl moiety is further substituted by a sulphamoyl or sulphonylamino group or by a ureido or acylamino group located at the para-position of the ring with respect to the aforesaid alkylamino side chain. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Methods for preparing all these compounds from know starting materials are provided.Type: GrantFiled: August 23, 1990Date of Patent: October 15, 1991Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4968704Abstract: A series of novel aryloxyalkylamino- and arylaminoalkylamino-pyridine and imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the aryl moiety is further substituted by a sulphamoyl or sulphonylamino group or by a ureido or acylamino group located at the para-position of the ring with respect to the aforesaid alkylamino side chain. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Methods for preparing all these compounds from known starting materials are provided.Type: GrantFiled: August 14, 1989Date of Patent: November 6, 1990Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4956382Abstract: A series of novel N-alkyl-N-(alkanesulphonamidoheterocyclicmethyl)-4-alkanesulphonamidophene tyl mines have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzo-fused heterocyclic group derived from either benzofuran, benzothiophene, benzoxazole or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred member compounds include N-methyl-N-(5-methanesulphonamidobenzofur-2-ylmethyl)-4-methanesulphonamid op henethylamine and N-methyl-N-(6-methanesulphonamidoquinol-2-ylmethyl)-4-methanesulphonamidop hen thylamine. Methods for preparing all these compounds from known starting materials are provided.Type: GrantFiled: February 2, 1988Date of Patent: September 11, 1990Assignee: Pfizer Inc.Inventors: John E. Arrowsmith, Peter E. Cross, Roger P. Dickinson, Geoffrey N. Thomas
-
Patent number: 4835165Abstract: A cardiac antiarrhythmic agent of the formula: ##STR1## or a pharmaceutically acceptable salt thereof; wherein R is R.sup.3 SO.sub.2 NH--, R.sup.3 CONH-- or R.sup.1 R.sup.2 NSO.sub.2 --;R.sup.1 and R.sup.2 are each independently H or C.sub.1 -C.sub.4 alkyl;R.sup.3 is C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl or --NR.sup.1 R.sup.2 where R.sup.1 andR.sup.2 are as defined above; andHet is either (a) a 2-, 3- or 4-pyridyl group optionally substituted by a C.sub.1 -C.sub.4 alkyl or an amino group, or (b) a 2-imidazolyl group optionally substituted by one or two C.sub.1 -C.sub.4 alkyl groups.Type: GrantFiled: March 30, 1988Date of Patent: May 30, 1989Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4806536Abstract: A series of novel 4-substituted piperazinyl-pyridine and 4-substituted piperazinyl-imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the 4-substituent is a lower phenylalkyl group or a derivative thereof further substituted on the phenyl moiety by a sulphamoyl or sulphonylamino group or by a nitro, amino or acetamido group. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrythmias. The most preferred member compound of the series is N-{4-[1-hydroxy-2-(4-[4-pyridinyl]-1-piperazinyl)ethyl]phenyl} methanesulphonamide. Methods for preparing all these compounds from known starting materials are provided.Type: GrantFiled: February 2, 1987Date of Patent: February 21, 1989Assignee: Pfizer, Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4788196Abstract: A series of pyridyl or imidazolyl substituted phenyl piperazines having utility as anti-arrhythmic agents is disclosed.Type: GrantFiled: April 17, 1987Date of Patent: November 29, 1988Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4647565Abstract: Dihydropyridines of the formulae ##STR1## wherein R is chlorothienyl or mono- or disubstituted phenyl where said substituent is fluoro, chloro, bromo or trifluoromethyl; R.sup.1 and R.sup.2 are each alykl; R.sup.3 and R.sup.4 when taken separately are each hydrogen or alkyl; R.sup.3 and R.sup.4 when taken together with the nitrogen to which they are attached are piperidine or pyrrolidine; R.sup.5 is alkyl or 2-hydroxyethyl; R.sup.6 is hydrogen or methoxy; X and Z are each hydrogen or methoxy; Y is alkylene; R.sup.7 is chlorophenyl or trifluoromethyl-chlorophenyl; p is 0 or 1; and Q is CH or N are useful in the treatment of hypertension, heart failure and angina.Type: GrantFiled: June 5, 1985Date of Patent: March 3, 1987Assignee: Pfizer Inc.Inventors: John E. Arrowsmith, Simon F. Campbell, Peter E. Cross, Roger P. Dickinson
-
Patent number: 4636500Abstract: N-(mono or disubstituted Phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis migraine and the vascular complications of diabetes.Type: GrantFiled: March 21, 1985Date of Patent: January 13, 1987Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4602016Abstract: N-(mono or disubstituted phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine, and the vascular complications of diabetes.Type: GrantFiled: November 19, 1979Date of Patent: July 22, 1986Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4590200Abstract: A novel series of carboxy-substituted naphthalenes and carboxy-substituted benzo-fused heterocycles, such as carboxy-substituted derivatives of indole, benzofuran and benzothiophene, has been prepared, including their pharmaceutically acceptable salts. These particular compounds are useful in therapy for the treatment of thrombosis, ischaemic heart disease, stroke, transient ischaemic attack, migraine, peripheral vascular disease, the vascular complications of diabetes and endotoxic shock. Preferred member compounds include 2-(1-imidazolylmethyl)-3-methylbenzo[b]thiophene-5-carboxylic acid and 3-methyl-2-(3-pyridylmethyl)benzo[b]thiophene-5-carboxylic acid, respectively. Methods for preparing these compounds from known starting materials are provided.Type: GrantFiled: October 22, 1984Date of Patent: May 20, 1986Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4555516Abstract: The N-(substituted benzyl) imidazoles are selective enzyme inhibitors and thus are useful in the treatment of heart disease, circulatory and vascular problems.Type: GrantFiled: January 9, 1980Date of Patent: November 26, 1985Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4551468Abstract: Heterocyclic thromboxane synthetase inhibitors of the formula ##STR1## wherein R.sup.1, which is attached to the 2-, 3- or 4-position, is hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, hydroxy or C.sub.1 -C.sub.4 alkoxy;Y, which is attached to the 2- or 3-position, is --COOH, --COO(C.sub.1 -C.sub.4 alkyl) or --CONH.sub.2 ;X is O, S, NH, N(C.sub.1 -C.sub.4 alkyl) or N(benzyl); andR, which is attached to the 5-, 6- or 7-position, is a group of the formula ##STR2## or (3- or 4-pyridyl)--Z.sup.2 -- wherein Z.sup.1 is --CH.sub.2 --, --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 O-- and Z.sup.2 is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 O-- or --OCH.sub.2 --;and their pharmaceutically acceptable salts; processes for their preparation, and pharmaceutical compositions containing them which are useful, for example, in the treatment of thrombosis.Type: GrantFiled: August 22, 1983Date of Patent: November 5, 1985Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson, Geoffrey N. Thomas
-
Patent number: 4496572Abstract: A novel series of carboxy-substituted naphthalenes and carboxy-substituted benzo-fused heterocycles, such as carboxy-substituted derivatives of indole, benzofuran and benzothiophene, has been prepared, including their pharmaceutically acceptable salts. These particular compounds are useful in therapy for the treatment of thrombosis, ischaemic heart disease, stroke, transient ischaemic attack, migraine, peripheral vascular disease, the vascular complications of diabetes and endotoxic shock. Preferred member compounds include 2-(1-imidazolylmethyl)-3-methylbenzo[b]thiophene-5-carboxylic acid and 3-methyl-2-(3-pyridylmethyl)benzo[b]thiophene-5-carboxylic acid, respectively. Methods for preparing these compounds from known starting materials are provided.Type: GrantFiled: August 9, 1982Date of Patent: January 29, 1985Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson
-
Patent number: 4451472Abstract: A series of novel 3-(1-imidazolylmethyl)indolylacrylic acid and 3-(3-pyridylmethyl)indolylacrylic acid derivatives has been prepared, including their pharmaceutically acceptable acid addition and base salts. These particular compounds are useful in therapy for the treatment of thrombosis, ischaemic heart disease, stroke, transient ischaemic attack, migraine, and the vascular complications of diabetes. Preferred member compounds include E-3-{1-[2-methyl-3-(1-imidazolylmethyl)]indolyl}-acrylic acid and E-3-{1-[2-methyl-3-(3-pyridylmethyl)]-indolyl} acrylic acid, respectively. Methods for preparing these compounds from known starting materials are provided.Type: GrantFiled: July 2, 1982Date of Patent: May 29, 1984Assignee: Pfizer Inc.Inventors: Peter E. Cross, Roger P. Dickinson